Prescribing information



Revolade® (eltrombopag olamine) Your Choice is a ‘dispense and deliver’ service provided by Novartis Pharmaceuticals UK Ltd., in partnership with Pharmaxo Pharmacy Service Ltd. and Lloyds Pharmacy Clinical Homecare Ltd.

It is a new patient support programme which is provided for your stable immune thrombocytopenia (ITP) patients, who are likely to remain on their current established dose of Revolade.


What are the benefits of Revolade Your Choice?

Patients receive their Revolade at home or another convenient location instead of in hospital, so they can continue with their normal daily routine and avoid unnecessary inconvenience:


Improve consistency in treatment


Improve patient’s quality of life


Save time and money for patients and their families, with no travel costs or missed days of work to pick up medication


Reduce the need for unnecessary hospital appointments


Patients can choose to have their medicine delivered to a preferred location, i.e. their place of work



How does it work?

Your patients will receive their Revolade through a courier service, as and when they need more medicine.

Homecare providers do not offer any incentives or encouragement to prescribe Revolade as part of this service.

There are no recommendations as to how the patient should take their medicine or manage their condition.

All further medical advice must be sought through and directed to the patient’s regular healthcare professional.



How can you set your patients up with Revolade Your Choice?


Complete an Expression of Interest form which you can receive from your local Novartis Disease Area Specialist.


The set up process will then be initiated between the homecare providers and the hospital trust homecare pharmacy team.


Once the service is available in your trust, the relevant homecare prescription will be made available.


What support is available for my patients through this service?

A range of resources are available to your patients to support them while managing their ITP. These will be provided to patients in their first delivery of Revolade. You may request further items through your local Disease Area Specialist or by contacting Novartis.



Dietary wheel

Patient information booklet



ITP Pocket Log

“Live life with ITP” patient resources, produced by Novartis


To organise a set-up meeting with the relevant partners, please complete the Expression of Interest contact here.

Please click here to complete the Expression of Interest contact form


If you wish to contact the providers, please contact:

Pharmaxo (For medicine delivery):
(Tel) 01225 302288
(Email) [email protected]

Lloyds Pharmacy Homecare Services:
(Tel) 0345 2636 123 or 0345 2636 135
(Email) [email protected]

Revolade is indicated for the treatment of patients aged 1 year and above with primary ITP lasting 6 months or longer from diagnosis and who are refractory to other treatments (e.g. corticosteroids, immunoglobulins)1


  1. REVOLADE FCT Summary of Product Characteristics.
Rate this content: 
No votes yet
UK | October 2021 | 167046

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]